Mathematical modelling for the assessment of the effect of drug application delays in metronomic chemotherapy of cancer due to physiological constraints

BioSystems

Volumn 91, Issue 1, 2008, Pages 108-116

  Mukherjee, Abhik ^a   Majumder, Durjoy ^a  

^a INDIAN INSTITUTE OF ENGINEERING SCIENCE AND TECHNOLOGY   (India)

Author keywords

Dose dense chemotherapy; Feedback control; Patho physiology; Tumour dynamics

Indexed keywords

ANTINEOPLASTIC AGENT;

ASSESSMENT METHOD; CANCER; DRUG; FEEDBACK MECHANISM; NUMERICAL MODEL; PHYSIOLOGY; TOXICITY; TUMOR;

ARTICLE; CANCER CHEMOTHERAPY; CELL KILLING; COMPUTER SIMULATION; DRUG CLEARANCE; DRUG EFFECT; FEEDBACK SYSTEM; KIDNEY FUNCTION; MATHEMATICAL MODEL; PHYSIOLOGY; QUALITY OF LIFE; THERAPY DELAY; TREATMENT OUTCOME; TUMOR CELL;

EID: 37349061349     PISSN: 03032647     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biosystems.2007.08.002     Document Type: Article

References (27)

1. Ben-Efraim S. Immunomodulating anticancer alkylating drugs: targets and mechanisms of activity. Curr. Drug Targets 2 (2001) 197-212
2. Ellis G.K., Livingstone R.B., Gralow J.R., Green S.J., and Thomson T. Dose dense anthracycline based chemotherapy for node positive breast cancer. J. Clin. Oncol. 20 (2002) 3637-3643
3. Filipovich A.H., Spector B.D., and Kersey J. Immunodeficiency in humans as a risk factor in development of malignancy. Prevent. Med. 9 (1980) 252-259
4. Forsling M.L., Montgomery H., Halpin D., Windle R.J., and Treacher D.F. Daily patterns of secretion of neurohypophysial hormones in man: effect of age. Exp. Physiol. 83 (1998) 409-418
5. Gately S., and Kerbel R. Anti-angiogenic scheduling of lower dose cancer chemotherapy. Cancer J. 7 (2001) 427-436
6. Hahnfeldt P., Folkman J., and Hlatky L. Minimizing long term tumour burden: the logic for metronomic chemotherapeutic dosing and its anti-angiogenic basis. J. Theor. Biol. 220 (2003) 545-554
7. Harris A.L., Reusch P., Barleon B., Hang C., Dobbs N., and Marme D. Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy. Clin. Cancer Res. 7 (2001) 1992-1997
8. Hornberg J.J., Bruggeman F.J., Westerhoff H.V., and Lankelma J. Cancer: a systems biology disease. BioSystems 83 (2006) 81-90
9. Kaplan D., and Glass L. One-dimensional differential equations. Understanding Nonlinear Dynamics (1995), Springer-Verlag, NY, Berlin, London pp. 147-207
10. Kaur H., and Budd T. Metronomic therapy for breast cancer. Curr. Oncol. Reports 6 (2004) 49-52
11. Keller E.F. The century beyond the gene. J. Biosci. 30 (2005) 3-10
12. Kerbel R.S., and Kamen B.A. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 4 (2004) 423-436
13. Kitano H. Cancer as a robust system: implications for anticancer therapy. Nat. Rev. Cancer 4 (2004) 227-235
14. Klement G., Baruchel S., Rak J., Man S., Clark K., Hicklin D.J., Bohlen P., and Kerbel R.S. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumour regression without overt toxicity. J. Clin. Invest. 105 (2000) R15-R24
15. Majumdar K.K., and Majumder D.D. Fuzzy differential inclusions in atmospheric and medical cybernetics. IEEE Trans. Syst. Man Cybernet. Part B 34 (2004) 877-887
16. Majumder D., and Mukherjee A. Patho-physiologically based logistics for treatment of cancer. J. Biol. Syst. 14 (2006) 631-650
17. Majumder D., and Mukherjee A. Simulation of drug administration delay in metronomic chemotherapy of cancer due to pathophysiological constraints. Proceedings of the First Int. Conf. Comput. Systems Biol. Shanghai, China (2006) 68-73
18. Man S., Bocci G., Francis G., Green S.K., Jothy S., Hanahan D., Bohlen P., Hicklin D.J., Bergers G., and Kerbel R.S. Antitumour effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res. 62 (2002) 2731-2735
19. MATLAB User's Guide, The Mathworks Inc., 2000.
20. Moon D.G., Jin M.H., Lee J.G., Kim J.J., Kim M.G., and Cha D.R. Antidiuretic hormone in elderly male patients with severe nocturia: a circadian study. BJU Int. 94 (2004) 571-575
21. Mukherjee A., Majumder D., and Icbal A. Exploring the effectiveness of low continuous chemo-bio-therapeutic treatment of cancer through analytical system modeling. J. Biol. Syst. 14 (2006) 1-12
22. Ogata K. Modern Control Engineering (1990), Prentice Hall, India
23. Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J. Support. Oncol. 1 (2003) 18-24
24. Stengel R. Optimal Control and Estimation (1994), Dover Publications, USA
25. Stoll B.R., Migliorini C., Kadambi A., Munn L., and Jain R.K. A mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumours: implications for antiangiogenic therapy. Blood 102 (2003) 2555-2561
26. Tao Y., Yoshida N., and Guo O. Nonlinear analysis of a model of vascular tumour and treatment. Nonlinearity 17 (2004) 867-895
27. Tulpule A., Groopman J., Saville M.W., Harrington Jr. W., Friedman-Kien A., Espina B.M., Garces C., Mantelle L., Mettinger K., Scadden D.T., and Gill P.S. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. Cancer 95 (2002) 147-154